{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:05:54Z","timestamp":1791068754764,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.eururo.2018.07.027","type":"journal-article","created":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T01:37:21Z","timestamp":1538444241000},"page":"44-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer"],"prefix":"10.1016","volume":"75","author":[{"given":"Lorenzo","family":"Tosco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony Vincent","family":"D\u2019amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Eastham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Eisenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gleave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Haustermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Ellen","family":"Taplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2018.07.027_bib0405","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2018.07.027_bib0410","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer, Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0415","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/annonc\/mds624","article-title":"Prostate cancer: ESMO Consensus Conference Guidelines 2012","volume":"24","author":"Horwich","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0420","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2012.08.001","article-title":"Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study","volume":"63","author":"Rider","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0425","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0430","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.eururo.2007.10.008","article-title":"Secondary therapy, metastatic progression, and cancer specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy","volume":"53","author":"Yossepowitch","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0435","doi-asserted-by":"crossref","first-page":"T209","DOI":"10.1530\/ERC-15-0217","article-title":"Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications","volume":"22","author":"Deng","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.eururo.2018.07.027_bib0440","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1158\/2159-8290.CD-13-0679","article-title":"Androgen receptor signaling fuels DNA repair and radioresistance in prostate cancer","volume":"3","author":"Bartek","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2018.07.027_bib0445","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1158\/1078-0432.CCR-04-2140","article-title":"Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer","volume":"11","author":"Eigl","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2018.07.027_bib0450","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0455","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2018.07.027_bib0460","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2018.07.027_bib0465","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0470","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","article-title":"Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017","volume":"73","author":"Gillessen","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0475","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"10.1016\/j.eururo.2018.07.027_bib0480","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2007.13.9881","article-title":"Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610","volume":"26","author":"Roach","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0485","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(11)70063-8","article-title":"Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial","volume":"12","author":"Denham","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0490","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.299.3.289","article-title":"Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial","volume":"299","author":"D\u2019Amico","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2018.07.027_bib0495","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","article-title":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma\u2014long-term results of phase III RTOG 85-31","volume":"61","author":"Pilepich","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 Suppl","key":"10.1016\/j.eururo.2018.07.027_bib0500","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.ijrobp.2015.07.106","article-title":"Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG oncology\/RTOG 9202","volume":"93","author":"Lawton","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2018.07.027_bib0505","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","article-title":"Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer","volume":"26","author":"Horwitz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0510","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2018.07.027_bib0515","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","article-title":"Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG oncology RTOG 9202","volume":"98","author":"Lawton","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2018.07.027_bib0520","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1016\/S1569-9056(16)60679-6","article-title":"Oncological outcomes in patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external beam radiation therapy followed by adjuvant continuous\/intermittent endocrine therapy in an open-label, randomized, phase III trial","volume":"15","author":"Ito","year":"2016","journal-title":"Eur Urol Suppl"},{"issue":"15_Suppl","key":"10.1016\/j.eururo.2018.07.027_bib0525","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2017.35.15_suppl.5008","article-title":"Duration of androgen deprivation therapy in high risk prostate cancer: final results of a randomized phase III trial","volume":"35","author":"Nabid","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0530","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/jama.2015.8577","article-title":"Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer","volume":"314","author":"D\u2019Amico","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2018.07.027_bib0535","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ejca.2015.03.021","article-title":"Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study","volume":"51","author":"Thomsen","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2018.07.027_bib0540","first-page":"CD006019","article-title":"Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer","volume":"4","author":"Kumar","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2018.07.027_bib0545","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1158\/1078-0432.CCR-16-1790","article-title":"A phase II, randomized, open-label study of neoadjuvant degarelix versus LHRH agonist in prostate cancer patients prior to radical prostatectomy","volume":"23","author":"Sayyid","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2018.07.027_bib0550","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0555","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4103\/1008-682X.160884","article-title":"Comparison of two adjuvant hormone therapy regimens in patients with high-risk localized prostate cancer after radical prostatectomy: primary results of study CU1005","volume":"18","author":"Chang","year":"2016","journal-title":"Asian J Androl"},{"key":"10.1016\/j.eururo.2018.07.027_bib0560","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1464-410X.2012.11536.x","article-title":"Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer","volume":"110","author":"Chen","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.07.027_bib0565","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clgc.2013.11.019","article-title":"Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma","volume":"12","author":"Marshall","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2018.07.027_bib0570","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.radonc.2010.08.012","article-title":"Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial","volume":"97","author":"Bolla","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0575","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0580","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejca.2011.10.015","article-title":"A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial","volume":"48","author":"Fizazi","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2018.07.027_bib0585","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"Suppl","key":"10.1016\/j.eururo.2018.07.027_bib0590","doi-asserted-by":"crossref","first-page":"LBA5002","DOI":"10.1200\/jco.2015.33.18_suppl.lba5002","article-title":"A phase III protocol of androgen suppression (AS) and 3DCRT\/IMRT versus AS and 3DCRT\/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521)","volume":"33","author":"Sandler","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.eururo.2018.07.027_bib0595","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1200\/JCO.2016.34.15_suppl.5001","article-title":"A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer: Results of SPCG12","volume":"34","author":"Ahlgren","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.eururo.2018.07.027_bib0600","first-page":"e1071","article-title":"VA CSP#553 chemotherapy after prostatectomy (cap) for high risk prostate carcinoma: a phase III randomized study","volume":"195","author":"Lin","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0605","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.eururo.2014.08.076","article-title":"Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe","volume":"67","author":"Fizazi","year":"2015","journal-title":"Eur Urol"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2018.07.027_bib0610","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1200\/JCO.2017.35.6_suppl.2","article-title":"Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: a phase III intergroup trial (SWOG S9921) NCT00004124","volume":"35","author":"Glode","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0615","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ijrobp.2015.05.024","article-title":"A phase 3 trial of 2 years of androgen suppression and radiation therapy with or without adjuvant chemotherapy for high-risk prostate cancer: final results of Radiation Therapy Oncology Group phase 3 randomized trial NRG Oncology RTOG 9902","volume":"93","author":"Rosenthal","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2018.07.027_bib0620","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials","volume":"10","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0625","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.eururo.2014.02.014","article-title":"Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS)","volume":"67","author":"Wirth","year":"2015","journal-title":"Eur Urol"},{"issue":"Suppl 6S","key":"10.1016\/j.eururo.2018.07.027_bib0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2018.36.6_suppl.1","article-title":"Ten year final results of the TROG 03.04 (RADAR) randomised phase 3 trial evaluating duration of androgen suppression \u00b1 zoledronate for locally advanced prostate cancer","volume":"36","author":"Joseph","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0635","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2018.07.027_bib0640","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2018.07.027_bib0645","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","article-title":"Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study","volume":"32","author":"Taplin","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0650","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1158\/1078-0432.CCR-16-1357","article-title":"Neoadjuvant enzalutamide prior to prostatectomy","volume":"23","author":"Montgomery","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2018.07.027_bib0655","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1016\/S1569-9056(16)15023-7","article-title":"Safety and efficacy of neoadjuvant chemohormonal and hormonal treatment followed by radical prostatectomy for patients with high- and very high risk prostate cancer: Initial results of prospective, randomized, phase III clinical trial","volume":"15","author":"Nosov","year":"2016","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2018.07.027_bib0660","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2003.10.013","article-title":"Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer","volume":"45","author":"Wirth","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0665","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ijrobp.2012.12.029","article-title":"Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study","volume":"86","author":"Corn","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6_Suppl","key":"10.1016\/j.eururo.2018.07.027_bib0670","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/jco.2013.31.6_suppl.150","article-title":"Concurrent treatment with everolimus (RAD001) and hormonoradiotherapy in high-risk locally advanced prostate cancer: results of a phase I trial","volume":"31","author":"Azria","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0675","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.ijrobp.2009.03.024","article-title":"Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer","volume":"76","author":"Carles","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2018.07.027_bib0680","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2016.69.0677","article-title":"Adding celecoxib with or without zoledronic acid for hormone-na\u00efve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial","volume":"35","author":"Mason","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0685","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.urology.2011.11.019","article-title":"Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109","volume":"79","author":"Berglund","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.07.027_bib0690","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1016\/j.juro.2013.02.330","article-title":"Feasibility of radical prostatectomy following neoadjuvant ixabepilone for high-risk prostate cancer: a phase II clinical trial","volume":"189","author":"Maddox","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0695","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1002\/cncr.27416","article-title":"Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial","volume":"118","author":"Ross","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2018.07.027_bib0700","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/pcan.2009.51","article-title":"Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life","volume":"13","author":"Ploussard","year":"2010","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7_Suppl","key":"10.1016\/j.eururo.2018.07.027_bib0705","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1200\/jco.2015.33.7_suppl.37","article-title":"Weekly paclitaxel versus ADT alone in localized high-risk prostate cancer: results of a single-institution phase II trial","volume":"33","author":"Saldana","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0710","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijrobp.2010.09.009","article-title":"Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy","volume":"82","author":"Hussain","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15_Suppl","key":"10.1016\/j.eururo.2018.07.027_bib0715","doi-asserted-by":"crossref","first-page":"e16620","DOI":"10.1200\/JCO.2016.34.15_suppl.e16620","article-title":"Results of a phase I-II trial using tri-modality therapy in patients with post-prostatectomy high risk pathologic (p) T2-3N0M0 prostate cancer","volume":"34","author":"Kumar","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0720","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/cncr.30620","article-title":"Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology\/RTOG study 0621","volume":"123","author":"Hurwitz","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2018.07.027_bib0725","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1002\/cncr.28270","article-title":"Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials","volume":"119","author":"Schweizer","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2018.07.027_bib0730","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/pcan.2015.23","article-title":"Integrating chemo-hormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer","volume":"18","author":"Zurita","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2018.07.027_bib0735","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-7-20","article-title":"Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer","volume":"7","author":"Thalgott","year":"2014","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0740","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7819-10-1","volume":"10","author":"Narita","year":"2012","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0745","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/pcan.2012.29","article-title":"Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study","volume":"15","author":"Koie","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2018.07.027_bib0750","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bju.12676","article-title":"Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer","volume":"116","author":"Silberstein","year":"2015","journal-title":"BJU Int"},{"issue":"Suppl 7","key":"10.1016\/j.eururo.2018.07.027_bib0755","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1200\/jco.2011.29.7_suppl.153","article-title":"On-target activity of neoadjuvant cixutumumab and combined androgen deprivation therapy for high-risk prostate cancer: a phase II trial","volume":"29","author":"Dean","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0760","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1634\/theoncologist.2011-0234","article-title":"Phase II trial of neoadjuvant docetaxel and CG1940\/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer","volume":"18","author":"Vuky","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2018.07.027_bib0765","doi-asserted-by":"crossref","first-page":"104182","DOI":"10.18632\/oncotarget.22115","article-title":"Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy","volume":"8","author":"Ross","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2018.07.027_bib0770","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-9-24","volume":"9","author":"Guttilla","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.eururo.2018.07.027_bib0775","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ijrobp.2009.11.011","article-title":"A Phase I trial of samarium-153-lexidronam complex for treatment of clinically non metastatic high-risk prostate cancer: first report of a completed study","volume":"79","author":"Valicenti","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2018.07.027_bib0780","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1016\/S0167-8140(16)31591-2","article-title":"Chemoradiotherapy in high-risk prostate cancer (QRT SOGUG trial): preliminary report","volume":"119","author":"Foro Arnalot","year":"2016","journal-title":"Radiother Oncol"},{"issue":"15_Suppl","key":"10.1016\/j.eururo.2018.07.027_bib0785","doi-asserted-by":"crossref","first-page":"TPS4701","DOI":"10.1200\/jco.2012.30.15_suppl.tps4701","article-title":"Randomized phase II clinical trial to assess MUC1 specific immune response to L-BLP25 vaccine in addition to standard therapy in newly diagnosed high-risk prostate cancer","volume":"30","author":"Singh","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5_Suppl","key":"10.1016\/j.eururo.2018.07.027_bib0790","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1200\/jco.2012.30.5_suppl.252","article-title":"A phase III randomized, open-label multicenter trial to evaluate the benefit of leuprorelin acetate for 24 months after radical prostatectomy in patients with high risk of recurrence (AFU-GETUG 20\/0310)","volume":"30","author":"Rozet","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl 6S","key":"10.1016\/j.eururo.2018.07.027_bib0795","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2018.36.6_suppl.88","article-title":"Adjuvant enzalutamide (Enza) for men with non-metastatic high-risk prostate cancer (HRPCa) after radical prostatectomy (RP)","volume":"36","author":"Ornstein","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6_Suppl","key":"10.1016\/j.eururo.2018.07.027_bib0800","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2017.35.6_suppl.16","volume":"35","author":"Guerif","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818305499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818305499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:05:34Z","timestamp":1759583134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283818305499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0302283818305499"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2018.07.027","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2018.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}